ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Kidney"

  • Abstract Number: 2911 • 2015 ACR/ARHP Annual Meeting

    Tubulointerstitial Involvement in Lupus Nephritis

    Angela Pakozdi1, Ravindra Rajakariar2, Michael Sheaff3 and Dev Pyne1, 1Rheumatology, Barts Health NHS Trust, London, United Kingdom, 2Renal Medicine, Barts Health NHS Trust, London, United Kingdom, 3Histopathology, Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: Tubulointerstitial disease is frequent in lupus nephritis (LN) with immune deposits being present in up to one third of patients.[1,2] Lesions including interstitial infiltration,…
  • Abstract Number: 2912 • 2015 ACR/ARHP Annual Meeting

    Concomitant Kidney Disease in Patients with Lupus Nephritis

    Paul Hoover1, Jose A. Gomez Puerta2, Alexander Fine1, Helmut Rennke3 and Karen H. Costenbader4, 1Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Grupo de Inmunología e Inmunogenética, GICIG, Universidad de Antioquia, Medellín, Colombia, Medellín, Colombia, 3Pathology, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology & Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: The most common and clinically and histologically best-characterized SLE kidney disease is lupus nephritis (LN).  However, other forms of kidney disease can and do…
  • Abstract Number: 2917 • 2015 ACR/ARHP Annual Meeting

    Combined Proliferative and Membranous Lupus Nephritis: Is the Prognosis Really Poor?

    Ryota Sakai1, Akiko Shibata1, Kentaro Chino1, Jun Kikuchi2, Tsuneo Kondo1, Ayumi Okuyama1, Hirofumi Takei1 and Koichi Amano1, 1Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, 2Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan

    Background/Purpose: Using light microscopy (LM) or immunofluorescence (IF), combined proliferative and membranous lupus nephritis (LN) is defined as an active proliferative class III/IV lesion and…
  • Abstract Number: 58 • 2015 ACR/ARHP Annual Meeting

    Attribution of Cause of End-Stage Renal Disease Among Systemic Lupus Erythematosus Patients

    Laura Plantinga1, Cristina Drenkard1, Stephen Pastan2 and S. Sam Lim3, 1Department of Medicine, Emory University, Atlanta, GA, 2Department of Medicine, Division of Renal Medicine, Emory University, Atlanta, GA, 3Emory University School of Medicine, Atlanta, GA

    Background/Purpose: The attributed cause of end-stage renal disease (ESRD) in the United States Renal Data System (USRDS) is often used to identify systemic lupus erythematosus…
  • Abstract Number: 606 • 2015 ACR/ARHP Annual Meeting

    Impaired Kidney Function Improves Treatment Response after 6 Months of Methotrexat Treatment in Rheumatoid Arthritis Patients

    Paul Studenic1, Farideh Alasti1, Josef S. Smolen2,3, Helmuth Haslacher4 and Daniel Aletaha5, 1Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 2Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, 32nd Department of Medicine, Hietzing Hospital, Vienna, Austria, 4Laboratory Medicine, Medical University Vienna, Vienna, Austria, 5Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria

    Background/Purpose: Methotrexate (MTX) and leflunomide are categorized as DMARDs of first choice in treating rheumatoid arthritis patients. MTX should be used cautiously in patients with…
  • Abstract Number: 991 • 2015 ACR/ARHP Annual Meeting

    CaMK4 Facilitates Recruitment of IL-17 Producing Cells to Target Organs through the CCR6/CCL20 Axis in Th17-Driven Inflammatory Diseases

    Tomohiro Koga1,2, Kotaro Otomo3, Masayuki Mizui2, Nobuya Yoshida4, José C. Crispin2, Atsushi Kawakami5 and George C. Tsokos4, 1Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 4Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan

    Background/Purpose: The recruitment of IL-17 producing T helper (Th17) cells to the inflammatory sites has been implicated in the development of organ damage in inflammatory…
  • Abstract Number: 1767 • 2015 ACR/ARHP Annual Meeting

    Noninvasive Assessment of Macrophage Activation in Experimental Glomerulonephritis Using Optical Imaging with Near-Infrared Light Serves As a Surrogate of Disease Activity

    Sebastian Braehler1, Dongyue Huang2, Matthew Cheung2, Walter Akers3 and Alfred Kim2, 1Pathology & Immunology, Washington University School of Medicine, Saint Louis, MO, 2Rheumatology, Washington University School of Medicine, Saint Louis, MO, 3Mallinckrodt Institute of Radiology, Washington University School of Medicine, Saint Louis, MO

    Background/Purpose: Glomerulonephritis (GN) represents a major cause of morbidity & mortality. The standard for diagnosing GN is through renal biopsy, but this is not performed…
  • Abstract Number: 1768 • 2015 ACR/ARHP Annual Meeting

    Improved Tissue Clearing and 2-Photon Imaging of Mouse Kidneys Reveals Immune Cell Architecture in Nephrotoxic Nephritis

    Matthew Cheung, Dongyue Huang and Alfred Kim, Rheumatology, Washington University School of Medicine, Saint Louis, MO

    Background/Purpose: Tissue clearing approaches such as CLARITY renders tissue transparent, and in combination with two-photon microscopy, enables microscopic visualization deep internal structures within unaltered organs.…
  • Abstract Number: 1850 • 2015 ACR/ARHP Annual Meeting

    Increased Levels of Immunoglobulin Binding Protein 1 Are Associated with Disease Activity Including Renal Damage in Patients with Systemic Lupus Erythematosus

    Eun-Ju Lee1,2, Seokchan Hong3, Doo-Ho Lim1, Yong-Gil Kim1, Chang-Keun Lee1 and Bin Yoo1, 1Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 2Asan Institute for Life Science, Asan Medical Center, Seoul, South Korea, 3Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea

    Background/Purpose: Systemic lupus erythematous (SLE) is a multisystem autoimmune inflammatory disease. Lupus nephritis (LN) is one of the most serious complications in patients with SLE.…
  • Abstract Number: 1911 • 2015 ACR/ARHP Annual Meeting

    Monocyte Chemoattractant Protein-1 (MCP-1, CCL2) Is a Potential Local Marker of Renal Involvement in Scleroderma

    Edward Stern1,2, Cassandra Hong2, Voon H. Ong2, Aine Burns1, Robert Unwin3 and Christopher P. Denton4, 1Nephrology, Royal Free Hospital, London, United Kingdom, 2Rheumatology, UCL Division of Medicine, London, United Kingdom, 3Nephrology, UCL Division of Medicine, London, United Kingdom, 4Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom

    Background/Purpose: Renal disease in scleroderma (SSc), including scleroderma renal crisis (SRC), remains a major clinical challenge. Previous studies showed up to 50% of SSc patients…
  • Abstract Number: 2016 • 2015 ACR/ARHP Annual Meeting

    Functional Tertiary Lymphoid Structures within the Kidneys of Lupus Prone Mice Resembles Lymph Nodes in Gene Expression Profiling Analysis and Are Detected By in Vivo Imaging

    Premasany Kanapathippillai, Sayed Esmaeil Dorraji and Kristin A Fenton, RNA and Molecular Pathology, UIT, The Artic University of Norway, Tromso, Norway

    Background/Purpose: The formation of tertiary lymphoid structures (TLS) are known to occur during the development of several diseases, including systemic lupus erythematosus (SLE), but in…
  • Abstract Number: 2191 • 2015 ACR/ARHP Annual Meeting

    Increased Risk of Acute and Chronic Renal Lesions Associated with Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis

    Vinicius Domingues1, DENIS WAHL2 and Stephane Zuily3, 1Rheumatology, New York University School Of Medicine, New York, NY, 2CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, Nancy, France, 3CHU de Nancy, Vascular Medicine Division and Regional Competence Centre For Rare Vascular And Systemic Autoimmune Diseases; and UMR_S U1116 Research Unit, France, Nancy, France

    Background/Purpose : Renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their associations with aPL are inconsistent among studies. Therefore our objective…
  • Abstract Number: 2349 • 2015 ACR/ARHP Annual Meeting

    The Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients with Severe Renal Impairment

    Ji Seon Oh and Seungwon Choi, Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea

    Background/Purpose:  Febuxostat has shown to be effective and safe in the treatment of hyperuricemia in patients with mild-to-moderate renal impairment without dose adjustment. However, there…
  • Abstract Number: 2350 • 2015 ACR/ARHP Annual Meeting

    Efficacy and Safety of Febuxostat in 55 Gouty Patients with Stage 4/5 Chronic Kidney Disease: Results from a Retrospective Multicenter Study

    Pierre-Antoine Juge1, Marie-Elise Truchetet2, Sébastien Ottaviani3, Cécile Vigneau4, Clotilde Loustau5, Divi Cornec6, Tristan Pascart7, Emilie Cornec-Legall8, Marine Florien9, Florian Bailly10, Thierry Schaeverbeke5, Alain Saraux11, Philippe Dieude12, Rene-Marc Flipo13, Georges Jean-Baptiste14, Pascal Richette15, Frederic Lioté16, Thomas Bardin17,18, Gerard H. Chales19 and Hang-Korng Ea20, 1Rheumatology Department, Centre de Viggo Petersen, Lariboisère Hospital, Paris, France, 2Rheumatology, Pellegrin Hospital, Bordeaux, France, 3Hopital Lariboisière, Paris, France, 4Nephrology, Rennes University Hospital, Rennes, France, 5Rheumatology Department, Bordeaux Hospital, Bordeaux, France, 6Department of rheumatology, Brest Occidentale University, Brest, France, 7Rheumatology, Saint-Philibert Hospital, Lille, France, 8Nephrology Departement, Brest Hospital, Brest, France, 9Rheumatology Department, Pierre-Zobda-Quitman La Meynard, Fort-de-France, France, 10Rheumatology Department, La Pitié-Salpétrière Hospital, Paris, France, 11Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 12Rheumatology, Bichat Claude-bernard, Universitary Hospital, APHP, Paris, France, 13Rheumatology, University Hospital, Lille, France, 14Rheumatology and Internal Medicine, Zobda Quitman Hospital, Fort-de-France, Martinique, 15Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, 16Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, 17Service de Rhumatologie, Hôpital Lariboisière, Paris, France, 18Rhumatology Departement, Hôpital Lariboisière, Paris, France, 19CHU RENNES, Rennes, France, 20INSERM UMR1132, Paris Diderot University, Paris, France

    Background/Purpose: Although allopurinol is the first urate lowering therapy (ULT), its limited dosage in gouty patients with stage 4 or 5 chronic kidney disease (CKD…
  • Abstract Number: 2356 • 2015 ACR/ARHP Annual Meeting

    Major Cardiovascular Events in Gout Patients with Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating on Allopurinol or Febuxostat (Uloric)

    JoAnne Foody1, Robin Turpin2, Beni Tidwell3 and Kathy Schulman4, 1Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Medical Affairs, Takeda Pharmaceuticals International, Deerfield, IL, 3ORS, Shrewsbury, MA, 4Outcomes Research Solutions, Inc., Waltham, MA

    Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and oxidative stress in the vasculature, both of which are cardiovascular disease (CVD) risk factors. However,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology